• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Amgen wins marketing authorization for Repatha single-dose delivery option

February 23, 2017 By Sarah Faulkner

AmgenAmgen wins marketing authorization for Repatha single-dose delivery option (NSDQ:AMGN) said today that the European Commission granted a change to the marketing authorization of its Repatha device, approving a single-dose delivery option. The pre-filled cartridge mini-doser is a hands-free device that is designed to provide 420 mg of Repatha (evolocumab) in a single injection for patients with cardiovascular disease.

The company touted its PCSK9 inhibitor as the 1st of its kind to offer a single monthly injection option in Europe.

The inhibitor is a human monoclonal antibody that blocks a protein which is responsible for blocking the body’s system that naturally eliminates low-density lipoprotein cholesterol.

“Amgen is committed to advancing care and improving the lives of patients with cardiovascular disease,” executive VP of R&D Dr. Sean Harper said in prepared remarks. “We are proud to bring this dosing alternative to patients in Europe, providing another option for them to incorporate Repatha into their cardiovascular care, with less frequent and hands-free administration.”

The Repatha mini-doser will be available in Europe this year, contingent upon reimbursement requirements, according to Amgen.

Repatha was the 1st PCSK9 inhibitor to win marketing authorization in Europe as an every-2-week or monthly dosing practice, the company reported. Repatha is approved as an add-on therapy to diet for patients with high cholesterol, in combination with statins or other lipid-lowering agents.

In July last year, the FDA approved the single-dose delivery option for Repatha using the on-body injection system Pushtronex.

Earlier this month, Amgen shares rose after the pharmaceutical company met expectations on Wall Street with its 4th quarter results and touted data from a trial for Repatha.

The Thousand Oaks, Calif.-based company posted profits of $1.94 billion, or $2.59 per share, on sales of $5.97 billion for the 3 months ended Dec. 31, for bottom-line growth of 8% on sales growth of 8% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $2.89, ahead of consensus on The Street, where analysts were looking for sales of $5.74 billion.

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS